Core Insights - Pfizer Inc. presented results from the Phase 3 BASIS study evaluating HYMPAVZI® (marstacimab) for adults and adolescents with hemophilia A or B with inhibitors, showing its superiority in improving key bleeding outcomes compared to on-demand treatment with bypassing agents [1] Group 1: Study Results - The Phase 3 BASIS study demonstrated that HYMPAVZI significantly improved bleeding outcomes [1] - HYMPAVZI is administered via a straightforward, once-weekly subcutaneous injection, requiring minimal preparation [1]